A Single-center, Randomized, Open-label, Parallel-controlled Study Was Conducted to Compare the Pharmacokinetics of JS002 When Delivered Subcutaneously Via a Prefilled Syringe Versus a Prefilled Autosyringe in Healthy Subjects
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Ongericimab (Primary)
- Indications Cancer; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IV
- Focus Pharmacokinetics
- Sponsors Shanghai Junshi Biosciences
Most Recent Events
- 02 Sep 2024 Status changed from active, no longer recruiting to completed.
- 24 Jun 2023 Status changed from not yet recruiting to active, no longer recruiting.
- 18 May 2023 New trial record